|
Celgene
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid ( lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company PM BMS, November 20, 2019; retrieved May 20, 2020 History Celgene was originally a unit of . In 1986, Celanese co ...[...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Celgene Logo
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid ( lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company PM BMS, November 20, 2019; retrieved May 20, 2020 History Celgene was originally a unit of . In 1986, Celanese co ...[...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Bristol Myers Squibb
The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the largest U.S. corporations. For fiscal 2021, it had a total revenue of $46.4 billion. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders. BMS's primary research and development (R&D) sites are located in Lawrence, New Jersey (formerly Squibb, near Princeton), Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey, Redwood City, California, and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts, East Syracuse, New York, Braine-l'Alleud, Belgium, Tokyo, Japan, Bangalore, India, and Wirral, United Kingdom. BMS previously had an R ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Thalomid
Thalidomide, sold under the brand names Contergan and Thalomid among others, is a medication used to treat a number of cancers (including multiple myeloma), graft-versus-host disease, and a number of skin conditions including complications of leprosy. While it has been used in a number of HIV-associated conditions, such use is associated with increased levels of the virus. It is taken by mouth. Common side effects include sleepiness, rash, and dizziness. Severe side effects include tumor lysis syndrome, blood clots, and peripheral neuropathy. Use in pregnancy may harm the fetus, including resulting in malformation of the limbs. In males who are taking the medication, contraception is essential if a partner could become pregnant. It is an immunomodulatory medication and works by a number of mechanisms, including stimulating T cells and decreasing TNF-α production. Thalidomide was first marketed in 1957 in West Germany, where it was available over the counter. When first ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Revlimid
Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). For multiple myeloma, it is used after at least one other treatment and generally with dexamethasone. It is taken by mouth. Common side effects include diarrhea, itchiness, joint pain, fever, headache, and trouble sleeping. Severe side effects include low blood platelets, low white blood cells, and blood clots. Use during pregnancy may harm the fetus. The dose may need to be adjusted in people with kidney problems. It has a chemical structure similar to thalidomide but has a different mechanism of action. How it works is not entirely clear as of 2019. Lenalidomide was approved for medical use in the United States in 2005. It is on the World Health Organization's List of Essential Medicines. Medical uses Multiple myeloma Lenalidomide is used to treat multiple myeloma. It is a more potent molecular analog of th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Lenalidomide
Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). For multiple myeloma, it is used after at least one other treatment and generally with dexamethasone. It is taken by mouth. Common side effects include diarrhea, itchiness, joint pain, fever, headache, and trouble sleeping. Severe side effects include low blood platelets, low white blood cells, and blood clots. Use during pregnancy may harm the fetus. The dose may need to be adjusted in people with kidney problems. It has a chemical structure similar to thalidomide but has a different mechanism of action. How it works is not entirely clear as of 2019. Lenalidomide was approved for medical use in the United States in 2005. It is on the World Health Organization's List of Essential Medicines. Medical uses Multiple myeloma Lenalidomide is used to treat multiple myeloma. It is a more potent molecular analog of th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Imnovid
Pomalidomide (INN; marketed as Pomalyst in the US and Imnovid in the European Union and Russia) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013, by the US Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma. It has been approved for use in people who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. It received a similar approval from the European Commission in August 2013. Origin and development The parent compound of pomalidomide, thalidomide, was originally discovered to inhibit angiogenesis in 1994. Based upon this discovery, thalidomide was taken into clinical trials for cancer, leading to its ultimate FDA approval for multiple myeloma. Structure-activity studies revealed that amino substituted thal ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Pomalyst
Pomalidomide (INN; marketed as Pomalyst in the US and Imnovid in the European Union and Russia) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013, by the US Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma. It has been approved for use in people who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. It received a similar approval from the European Commission in August 2013. Origin and development The parent compound of pomalidomide, thalidomide, was originally discovered to inhibit angiogenesis in 1994. Based upon this discovery, thalidomide was taken into clinical trials for cancer, leading to its ultimate FDA approval for multiple myeloma. Structure-activity studies revealed that amino substituted thal ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Demcizumab
Demcizumab is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene. Mechanism of action Demcizumab blocks Delta-like ligand 4 (DLL4), a ligand of Notch receptors. Notch signaling has been implicated as a key signaling pathway in cancer stem cells. By treating patients with a combination of Demcizumab and a cytotoxic chemotherapy, it is hoped that a more durable anti-tumor response can be achieved than with chemotherapy alone. Adverse effects Demcizumab has been known to cause many adverse effects in patient. The most common side effects are hypertension, fatigue, anemia, and headaches. More adverse effect are nausea, hypoalbuminemia, dizziness, and dyspnea occurred. Finally, some uncommon side effects are heart related illness forming half way th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
OncoMed
OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. , the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by Mereo BioPharma and delisted from the Nasdaq. History Oncomed was founded in 2004. In 2007, Oncomed consolidated its operations located in Mountain View and Palo Alto, California onto the single headquarters campus at Seaport Centre in Redwood City. One of the buildings on the new campus was the former home of NeXT. I ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Idhifa
Enasidenib (INN; trade name Idhifa) is a medication used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test. It is an inhibitor of IDH2. It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical use Enasidenib is used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the IDH2 gene, determined by an FDA-approved IDH2 companion diagnostic test. Adverse effects The main serious adverse effect of enasidenib is differentiation syndrome. Pharmacology Isocitrate dehydrogenase is a critical enzyme in the citric acid cycle. Mutated forms of IDH produce high levels of the (''R'')-enantiomer of 2-hydroxyglutarate (R-2-HG) and can contribute to the growth of tumors. IDH ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Summit, New Jersey
Summit is a city in Union County, in the U.S. state of New Jersey. The city is located on a ridge in northern- central New Jersey, within the Raritan Valley and Rahway Valley regions in the New York metropolitan area. At the 2010 United States census, the city's population was 21,457,DP-1 - Profile of General Population and Housing Characteristics: 2010 for Summit city, Union County, New Jersey , . Accessed February 21, 2012. [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Celanese
Celanese Corporation, formerly known as Hoechst Celanese, is an American technology and specialty materials company headquartered in Irving, Texas. A Fortune 500 corporation, the company is the world’s leading producer of acetic acid, producing about 1.95 million tonnes per year, representing approximately 25% of global production. Celanese is also the world's largest producer of vinyl acetate monomer (VAM). Celanese operates 25 production plants and six research centers in 11 countries, mainly in North America, Europe, and Asia. The company owns and operates the world's three largest acetic acid plants: one in the Clear Lake area of Pasadena, Texas, one on Jurong Island in Singapore, and a third in Nanjing, China. History In 1918, the American Cellulose & Chemical Manufacturing Company (known as Amcelle) was founded in New York City by Swiss chemist Camille Dreyfus. The American Cellulose and Chemical Manufacturing Co. Ltd plant in Cumberland, Maryland, was set up dur ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
.jpg "Click for more on -> Bristol Myers Squibb")
